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Abstract 
Background and Aim: Patients with blood coagulopathies treated with multiple transfusions have a high risk to 
acquire some viral infections such as hepatitis C. This research was aimed to identify hepatitis C virus (HCV) 
infection prevalence, and the viral genotypes among patients with hemophilia and other inherited coagulopathies in 
Mashhad, Iran. 
Methods: Medical records of 760 patients with inherited coagulopathies including hemophilia were reviewed in 
Sarvar Clinic of Mashhad. Plasma samples were subjected to detect antibodies against HCV (anti-HCV) by enzyme-
linked immunosorbent assay. HCV RNA and genotypes were determined by a real-time polymerase chain reaction 
(PCR) method.  
Results: Totally 128 individuals (16.8%) including patients with hemophilia (n=116) and individuals with other 
coagulopathies (n=12) were found to be seropositive for anti-HCV. They comprised 122 men and six women with a 
mean age of 31.6 ± 10.5 years. The PCR results were available for 118 patients, of whom 86 individuals (72.9%) were 
found to have detectable HCV RNA in their serum. The most frequent genotypes were 1a and 3a (49.1% and 35.8%, 
respectively). HCV genotypes were not significantly correlated with the patients’ age (p=0.477) as well as with the 
serum levels of alanine aminotransferase (p=0.655) and aspartate aminotransferase (p=0.332).  
Conclusion: The patients with blood coagulation disorders had a greater prevalence of HCV infection in comparison 
with the general population in our region. The most common subgenotypes of HCV were 1a, and 3a, respectively. 
These results could assist professionals to choose more efficient approaches for the management of their patients. 
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Hepatitis C virus (HCV) infection is a global health 
problem affecting 71 million people worldwide.  In 
2015, it is estimated that 1.75 million people were 
newly infected with HCV and 399 000 deaths 
occurred due to disorders related to chronic 
hepatitis C such as cirrhosis and hepatocellular 
carcinoma (1).  
Iran has been considered as an area with a low 
frequency of HCV infection. According to a 
systematic review by Mirminachi et al., the overall 
prevalence of seropositivity for antibodies against 
HCV (anti-HCV) and HCV viremia was 0.6% and 
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0.4%, respectively, in the general Iranian 
population (2).  
Another systematic review estimated previously the 
overall prevalence of HCV infection as 0.5% 
among Iranian blood donors (3). However, some 
healthcare-related contacts are suggested to be 
responsible for a significant portion of HCV 
spreading in Iran. In comparison with the general 
population, the odds ratio of HCV infection was 
estimated to be 39.3 (95% CI: 25.7-60.2) among 
Iranian populations at high risk of healthcare-
related exposures (4). Populations with frequent 
blood transfusion are at higher risk of several 
transfusion-transmitted infections including viral 
hepatitis. (5). In comparison with the general 
population, higher prevalence rates of anti-HCV 
have been reported among patients with blood 
disorders such as hemophilia in Middle East and 
North Africa countries.(6)  
Another systematic review estimated a total HCV 
prevalence of 20.0% (95% CI: 16.4-23.9%) among 
Iranian multi-transfused patients; the rate for 
hemophiliacs was reported as 6.0% to 90.0%, with 
a median of 54.0% (4). In fact, patients with 
inherited coagulopathies such as hemophilia are at 
extreme risk of HCV infection because of their 
lifelong requirements of blood transfusion. 
HCV has been classified into some major genotypes 
and subtypes based on genomic heterogeneity (7). 
Determination of HCV genotypes may have 
important implications for the prognosis and anti-
viral therapies and may show the routes of 
acquisition. HCV genotype 1 (G1) has been found 
to be the most frequent in the world (46-49%), 
followed by G3 (18-22%), G4 (13-17%), G2 (11-
13%), and G5 and G6 (together < 5%) (8, 9).  
The distribution of HCV genotypes varies based on 
geographical regions as well as on the demographic 
differences in the affected populations. HCV G1 to 
G3 distribute all over the world but G4 to G6 are 
restricted to certain geographical regions (8). In 
Iran, both large-scale surveys and systematic 
reviews indicated that the highest proportion of 
HCV infection is associated with G1 and G3 (4, 10-
12).  
Regarding HCV subgenotypes, subtype 1a (39-
45%) followed by 3a (27-40%) and 1b (11-13%) 
are the most predominant reported subtypes in our 
country (10-13). However, the subgenotypes 
frequency differences have been reported among 
HCV-positive Iranian patients with hemophilia and 
other inherited bleeding disorders (58-65%, 18-
19%, and 14-15%, respectively) (14, 15).  
In Mashhad, Northeastern Iran, a big city with a 
significant low prevalence of HCV infection among 
the general population (0.42%, 95% CI: 0.17-
0.87%) (16), the same rates were reported for 1a 
(39.2%) and 3a (40%) subtypes followed by 1b 
(10.9%) (17).  
Nevertheless, there is no adequate data of patients 
with congenital bleeding disorders in this city 
regarding HCV genotypes distribution. The present 
study was performed to determine the prevalence of 
HCV infection and the distribution of viral 
genotypes in patients with hemophilia and other 
inherited blood coagulopathies in Mashhad, Iran. 
Methods 
In this cross-sectional study, the medical records of 
all 760 patients with congenital bleeding disorders 
were reviewed in the Sarvar Clinic of Mashhad, 
Iran, in 2011.  
The participants included the patients with 
hemophilia A or B and other blood coagulopathies 
such as Von Willebrand disease, factor V 
deficiency, and platelet disorders. The serum 
samples of patients were tested routinely to detect 
common transfusion-transmitted viral pathogens 
using enzyme-linked immunosorbent assay (DiaPro 
Diagnostic Bioprobes Srl, Italy, for antibodies 
against HCV). 
The seropositive specimens were further tested by a 
polymerase chain reaction (PCR) method to 
confirm current HCV infection, and HCV-RNA 
positive samples were assessed to determine virus 
genotypes by a real-time PCR assay (artus® HCV 
RG RT-PCR, QIAGEN GmbH, Germany, and 
Genotype Assay Kit, Novin Gene, Iran). Serum 
levels of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were also 
measured and a value of 40 mg/dl was considered 
as upper normal limits for both tests.  
Statistical Analysis 
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Using SPSS version.16.0 software, data were 
described as percentages or mean ± standard 
deviations. Interrelation between HCV genotypes 
and some independent factors was assessed using 
the chi-square test, and if required, Fisher’s exact 
test, p-values less than 0.05 were considered 
statistically significant. 
Results 
Serum HCV antibodies were detected in 128 of 760 
patients (16.8%). The range of seropositive 
patients’ age at the time of the study was 2-64 
years.  
The demographic and clinical data of hemophilia 
and blood coagulopathies patients with anti-HCV 
seropositivity in Mashhad, Iran has been shown in 
Table 1. One-hundred thirteen patients had clotting 
factor deficiencies and 15 individuals were 
suffering from blood platelet disorders. Abnormal 
high levels of serum AST and ALT were observed 
in 23.9% and 27.4% of the 117 HCV seropositive 
patients, respectively.  
The PCR results were available for 118 individuals, 
of whom HCV RNA was detected in 86 patients 
(72.9%). The genotyping data were available in 53 
of 86 HCV-RNA positive patients, presented 
subtypes 1a (49.1%) and 3a (35.8%) as the most 
frequent viral subgenotypes (Figure 1). The mean of 
ages was the same in the patients infected with 
HCV subtypes of 1a (33.3±10.2) and 3a (31.1±10.4, 
p=0.477).  
No significant difference was observed between the 
patients with HCV subtypes of 1a and 3a regarding 
the frequency of abnormal levels of serum ALT 
(40.0% vs. 33.3%, p=0.655) and AST (36.0% vs. 
22.2%, p=0.332).  . 
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Table 1. Demographic and clinical data of hemophilia and blood coagulopathies patients with anti-HCV 
seropositivity in Mashhad, Iran 
Variables Number Percent (%) 
Age (years, Mean, SD, n = 127) 31.6 10.5 
Gender (n = 128)   
Men 122 95.3 
Women 6 4.7 
Type of bleeding disorder (n = 128)   
Hemophilia A 75 58.6 
Hemophilia B 30 23.4 
Other factors deficiencies 8 6.3 
Platelets disorders 15 11.7 
Serum ALT (mg/dl, n = 117)   
<= 40  85 72.6 
> 40 32 27.4 
Serum AST (mg/dl, n = 117)   
<= 40  89 76.1 
> 40 28 23.9 
Serum HbsAg (n = 107)   
Negative  105 98.1 
Positive  2 1.9 
Serum anti-HIV (n = 113)   
Negative  112 99.1 
Positive  1 0.9 
Serum HCV RNA (n = 118)   
Positive  86 72.9 
Negative  32 27.1 
HCV subgenotypes (n = 53)   
1a 26 49.1 
1 b 2 3.8 
3a 19 35.8 
Mixed  4 7.6 
Non-typeable 2 3.8 
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase, HbsAg: Surface antigen of hepatitis B 
virus; HIV: Human immunodeficiency virus; SD: Standard deviation 
 
Discussion 
Patients with hemophilia and other coagulopathies 
who are treated with multiple transfusions are at 
higher risk of HCV infection (5). A meta-analysis 
in 2009 demonstrated that the overall prevalence of 
anti-HCV seropositivity among Iranian patients 
with hemophilia is as high as 40.8% (18). In the 
present study, HCV antibodies were detected in the 
serum samples of 16.8% of patients with blood 
coagulopathies in Mashhad, northeast of Iran, with 
72.9% HCV viremia among anti-HCV seropositive 
individuals. These rates of anti-HCV seropositivity 
and active HCV infection were significantly higher 
than those reported among the general population of 
this city  (0.7% and 0.4%, respectively) (16). 
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Nevertheless, HCV infection prevalence among our 
patients was significantly lower than the average 
rate (54.0%) reported for hemophiliacs in our 
country (4).  
According to the global health sector strategies on 
viral hepatitis, HCV diagnosis is one of the 
important steps to reach the goal of viral hepatitis 
ending in the world by 2030 (19). Furthermore, 
based on the World Health Organization guidelines, 
detection of HCV genotypes is needed to choose the 
appropriate direct-acting antiviral drugs for the 
treatment of the patients (20). In our population, 
subtype 1a (49.1%) was the most common HCV 
type followed by 3a (35.8%), mixed (7.6%), 1b 
(3.8%) and unclassified genotypes (3.8%). The 
distribution of HCV subgenotypes in this survey 
was generally similar to those reported previously 
from other parts of Iran; however, the prevalence 
rate of subtype 3a in our study was higher than that 
detected by the other investigations. For instance, 
Samimi-Rad et al. in 2016 reported that subtypes 1a 
(65.0%), 3a (18.7%), and 1b (14.5%) were the most 
frequent HCV subgenotypes in 229 HCV positive 
patients with inherited bleeding disorders at a major 
referral clinic of Tehran, north of Iran (14). In 2010, 
another study among 367 Iranian HCV-positive 
patients with inherited coagulopathies, identified 
subtype 1a as the most HCV subgenotype (58.0%), 
followed by 3a (18.5%) and 1b (14.7%) (15). 
Assarehzadegan et al. found a similar distribution of 
HCV genotypes among hemophilia patients in 
Ahvaz, southwest Iran, during 2008-2009. 
However, the rate of infection with HCV 1b 
(26.1%) was more common than HCV 3a (11.9%) 
(21). In contrast, a survey from Mazandaran 
province, north of Iran, performed between 2009-
2011, reported a higher rate of HCV infection with 
subtype 3a as compared to 1a among all 135 HCV 
RNA-positive patients (51.1% vs. 27.4%) as well as 
a subgroup of 33 HCV-positive patients with 
hemophilia (75.8% vs. 21.2%) (22). In 2011, 
another study from Fars province, south of Iran, 
showed the higher rate of HCV infection belonging 
to subtype 3a (40.9%) in comparison with 1a 
(26.2%) and 1b (8.7%) (23). These discrepancies 
could be partly due to the differences in the routes 
of transmission, and various socioeconomic factors 
(10,14). For example, Ziyaeyan et al. believed that 
finding a higher proportion of subtype 3a than 1a in 
their HCV-positive patients referred to a major 
tertiary teaching hospital in Shiraz, southern Iran, 
maybe because of a considerable percentage of 
injecting drug users (38.8%) in their region (23). 
The pattern of HCV genotypes among our patients 
seems to be comparable with western countries 
where subtypes 1a and 3a are dominant among 
people with HCV infection (9). In Iran’s 
neighboring countries, however, diverse patterns 
have been reported. In a study conducted during 
January to December 2006 in Pakistan, in the 
neighborhood of Eastern Iran, most of the 
hemophilia patients with HCV infection 
demonstrated subtype 3a (38%), though the virus 
type could not be determined in 52.4% of positive 
individuals (24). On the other hand, G4 is the most 
common HCV type reported among hemophilia 
patients in some of our neighboring Arab countries 
like Iraq (25), Jordan (26), and Lebanon (27).  
In the current study, mixed genotypes were detected 
in 7.6% of the patients which was compatible with 
previous reports (11, 22). Keshvari et al., detected 
mixed HCV genotypes among 6.2% of Iranian 
patients with blood coagulopathies (15). Infection 
with two or more HCV subgenotypes might happen 
in high-risk groups with multiple exposures to the 
virus such as hemophilia, thalassemia, hemodialysis 
patients, and intravenous drug abusers (12, 22).  
In this study, we could not find any significant 
interrelation between infection with different HCV 
subgenotypes and patients’ age as well as abnormal 
serum levels of aminotransferase. Similarly, another 
study from Iran reported no significant association 
between patients’ age and the liver biochemical 
profile and HCV genotypes among patients with 
congenital bleeding disorders patients with chronic 
HCV infection (15).  
Conclusion 
Our study revealed a higher rate of HCV infection 
prevalence among patients with inherited 
coagulopathies than the general population in 
Northeastern Iran. In accordance with other parts of 
the country, the most common subgenotypes of HCV 
were 1a and 3a subtypes. It seems that more strict 
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preventive measures should be taken into account in 
our country to reduce HCV spread, especially among 
multi-transfused patients. These measures may include 
HCV screening using more sensitive methods to detect 
infection during the window phase, implementing 
more effective virus inactivation or virus removal 
techniques in blood centers, and developing new 
treatment plans for the patients affected with this 
virus. 
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